Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01275 (glucagon)
 26,492 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The performed studies covered 28 patients with nephrotic syndrome and 10 healthy individuals. The oral glucose tolerance test in 20 patients with nephrotic syndrome revealed glycemic values within the norm, and features of defective tolerance to glucose or diabetes in 8 subjects. Hyperglucagonemia was recorded in all the patients with increased glycemic values in the oral glucose tolerance test. It was found that hyperglucagonemia appeared in 70% of studied patients with normal glucose tolerance. All the groups of patients with nephrotic syndrome disclosed a decrease in glucagonemia, observed in normal subjects, in the course of oral glucose tolerance test as well as slower disappearance of glucagon from the circulatory system, which may be of certain significance in the occurrence of hyperglucagonemia. It has been ascertained that hyperglucagonemia may be one of the factors having influence upon a higher incidence rate of glucose tolerance abnormalities than in general population; can have a share in intensified catabolic processes, and also counteracts the effects of increased tissue absorption of glucose in patients with nephrotic syndrome. There has been a lower stimulating action of exogenic glucagon on insulin secretion in patients with nephrotic syndrome and hyperglucagonemia as compared to patients with normoglucagonemia and to healthy subjects.
 ...
PMID:[Glucagon secretion in patients with nephrotic syndrome in primary glomerulonephritis during the period of renal efficiency]. 209 3

Hypertriglyceridaemia is often observed in patients (1) with chronic renal insufficiency, (2) on haemodialysis and (3) after successful renal transplantation. HDL cholesterol is reduced in all three groups of patients and plasma cholesterol is elevated after renal transplantation. In these three patient groups type IV hyperlipoproteinaemia is found most frequently and after renal transplantation there is a relative increase in the incidence of type II hyperlipoproteinaemia. The role of glucagon resistance and carnitine deficiency in the alteration of fat metabolism seen in patients with chronic renal failure and patients on haemodialysis is discussed. Other factors which may influence fat metabolism in uraemia include calcium and vitamin D status as well as beta adrenergic receptor blocking agents and diuretics. Steroid therapy may be one cause of the hypercholesterolaemia and hypertriglyceridaemia seen after renal transplantation. PHLP lipase activity is reduced in all three groups of patients. In nephrotic syndrome, if hypercholesterolaemia occurs, the HDL cholesterol fraction is increased and thus the cardiovascular risk may be lower than in the three patient group mentioned above.
 ...
PMID:[Alterations of fat metabolism in renal disease - pathogenetic mechanisms (author's transl)]. 612 54